Agilent Technologies Inc vs Global X Robotics and Artificial Intelligence ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Global X Robotics and Artificial Intelligence ETF trades at $37.48. The key difference: Agilent Technologies Inc pays a 0.69% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| A | BOTZ | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | — |
52-Week High | $157.20 | $41.63 |
52-Week Low | $110.24 | $31.99 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
BOTZ trades at $37.61, up 1.81% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, offering exposure to global leaders in automation. Recent news highlights its role in the expanding AI and robotics theme, with comparisons to peers like ARKQ and ROBO. A small dividend is scheduled for 2026.
Outlook is positive due to growth in AI and robotics adoption, but risks include high valuation sensitivity and sector competition. Investors should weigh the thematic growth potential against market volatility and the ETF's expense structure.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →